Immunization Branch
|
 |
|
Benefit-Cost Analysis of Commonly Used Vaccines
(Savings
Per Dollar Invested*)
|
VACCINE
|
DIRECT MEDICAL SAVINGS
|
DIRECT + INDIRECT * SAVINGS
|
DTaP
|
$ 9.00
|
$27.00
|
MMR (includes 2nd dose)
|
$14.20
|
$26.00
|
IPV
|
$ 3.03
|
$ 5.45
|
H. INFLUENZAE TYPE b
|
$ 3.40
|
$ 5.40
|
HEPATITIS B
PERINATAL
INFANT
ADOLESCENT
|
$1.40
$0.90
$0.50
|
$14.70
$5.10
$3.80
|
VARICELLA
|
$ 0.90
|
$ 5.40
|
* Indirect savings include workloss, disability, and death
SOURCE: 
National Immunization
Program, Centers for Disease Control and Prevention, October 2003
Record
|
Legislation
|
Name and, if appropriate title of the health care provider who
administers the vaccine
Address where vaccine given (in the case of outreach clinics,
address should be the clinic site where the record will reside)
Date of vaccination
Manufacturer and lot number of vaccine
|
1986 National Childhood Vaccine Injury Act (NCVIA) 42 U.S.C. §
300aa-25
|
Edition (date of publication) of Centers for Disease Control
and Prevention (CDC) Vaccine Information Statement (VIS)* provided
and date provided.
|
1994 amendment to 42 U.S.C. Sec. 2125. §
300aa-25
|
Site and route of administration
|
Not required, but recommended. Information requested for
reports to Vaccine Adverse Event Report System
(VAERS).
|
VACCINE/TOXOID
|
DATE
|
Bacillus Clamette-Guerin Vaccine
|
1921
|
Diphtheria Toxoid
|
1926
|
Tetanus Toxoid
|
1933
|
Tetanus and Diphtheria Combined Toxoid
|
1934
|
Influenza Vaccine
|
1945
|
Pertussis Vaccine
|
1949
|
Tetanus, Diphtheria Toxoid and Pertussis Vaccine
|
1949
|
Mumps Vaccine, inactivated
|
1950
|
Inactivated Poliomyelitis Vaccine (Salk)
|
1955
|
Oral Poliomyelitis Vaccine (Sabin)
|
1961
|
Trivalent Oral Polio Vaccine
|
1963
|
Measles Vaccine, live
|
1963
|
Measles Vaccine, inactivated
|
1963
|
Mumps Vaccine, live
|
1967
|
Rubella Vaccine, live
|
1969
|
Measles-Rubella Combined Vaccine, live
|
1971
|
Measles-Mumps-Rubella Vaccine, live
|
1971
|
Pneumococcal Vaccine (14-valent)
|
1977
|
Human Diploid Cell Vaccine (Rabies Vaccine)
|
6/80
|
Hepatitis B Vaccine
|
11/81
|
Pneumococcal Vaccine (23-valent)
|
1983
|
Haemophilus influenzae Type b Polysaccharide
Vac.
|
4/85
|
Enhanced-Inactivated Poliomyelitis Vaccine
|
11/85
|
Hepatitis B Vaccine (RECOMBIVAX HB®)
|
7/86
|
IPOLTM
PoliovaxTM
|
1987
|
Haemophilus influenzae Type b Conjugate
Vaccine
|
12/87
|
Diphtheria-Tetanus-Pertussis (Acellular) Vaccine
|
12/17/91 (Lederle)
8/21/92 (Connaught)
|
Diptheria-Tetanus-Pertusis Haemophilus influenzae
Type b Conjugate Combination Vaccine
|
3/30/93
11/93 (2nd product)
|
Hepatitis A Vaccine - 3 dose schedule (SmithKline
Beecham)
|
2/95
|
Varicella Vaccine
|
3/17/95
|
Hepatitis A Vaccine - 2 dose schedule (Merck Vaccine
Division)
|
3/29/96
|
Diphtheria-Tetanus-Pertussis (Acellular) Vaccine for
infants
|
7/31/96 (Connaught)
|
Diphtheria-Tetanus-Pertussis (Acellular)/ Haemophilus
influenzae Type b Conjugate Combination Vaccine (4th dose at 15 to 18
months)
|
9/30/96
|
Haemophilus influenzae type b conjugate
(Meningococcal Protein Conjugate) and Hepatitis B (Recombinant Vaccine)
COMVAX
|
10/02/96
|
Diptheria & Tetanus Toxoids Adsorbed (Chiron Behring GmbH
- with SKB)
|
1/29/97
|
Diphtheria-Tetanus-Acellular Pertussis (Infanrix) (Chiron
Behring GmbH-with SKB)
|
1/29/97
|
Diphtheria & Tetanus Toxoids Adsorbed (Connaught Labs.
Ltd) (Children, 6 weeks to 7 years of age).
|
4/11/97
|
Rabies Vaccine (Chiron Behring GmbH-Germany)
|
10/97
|
Rotavirus Vaccine (Wyeth-Lederle: RotaShield)
|
8/31/98
|
Hepatitis B Vaccine - Merck - 5.0 mcg for ages 0-19 years
old
|
8/98
|
Lyme Vaccine (SmithKline Beecham Biologicals:
LYMErix)
|
12/21/98
|
Pneumococcal Conjugate Vaccine (Wyeth-Lederle:
PrevnarTM)
|
2/17/2000
|
SOURCE: U.S. Department of Health and Human Services, Public
Health Service, Food and Drug Administration
Texas Department of State Health
Services, Immunization Branch (as of February 22, 2000).